Innovative Cancer Care: Digital Tools & Research Backed by Gilead
Dr. Maria Alice Franzoi, a medical oncologist with experience practicing in three different countries, brings a deep understanding of diverse healthcare systems. She is particularly passionate about exploring patient-centered care approaches and the integration of cutting-edge digital health solutions.
“Technology has the potential to transform healthcare into a more proactive system,” Maria explains.
With backing from the Gilead Research Scholars Program (RSP), Maria is implementing a remote monitoring initiative designed to enhance cancer treatment by shifting care from hospitals to local primary care facilities. This program has already been rolled out in multiple European centers, positively impacting the lives of patients with breast cancer by improving their overall well-being.
Gilead is committed to pushing the boundaries of scientific discovery, often looking beyond internal research to address gaps in oncology treatment. Since 2008, the company has supported early-stage researchers through the RSP, including Maria and Dr. Katherine Chiappinelli, an assistant professor at George Washington University. Katherine’s work focuses on ovarian cancer, and through the RSP, she is advancing research into epigenetic therapies aimed at stimulating the immune system to combat the disease.
Another RSP recipient, Dr. Neil Vasan—a physician-scientist at Columbia University Irving Medical Center—is exploring the role of oncoproteins in cancer signaling. His research zeroes in on rare PIK3CA mutations, and he is building a detailed “PIK3CA mutation playbook” to help inform breast cancer treatment decisions.
“Funding matters for several reasons,” Neil says. “It validates that your research is promising and could lead to meaningful change.”
Currently, Gilead’s oncology portfolio includes around 30 clinical-stage programs and over 20 potential therapies, covering a wide range of cancer types, particularly those with significant unmet needs.
Watch the video above to discover more about how Gilead continues to foster innovation in cancer research.
“Technology has the potential to transform healthcare into a more proactive system,” Maria explains.
With backing from the Gilead Research Scholars Program (RSP), Maria is implementing a remote monitoring initiative designed to enhance cancer treatment by shifting care from hospitals to local primary care facilities. This program has already been rolled out in multiple European centers, positively impacting the lives of patients with breast cancer by improving their overall well-being.
Gilead is committed to pushing the boundaries of scientific discovery, often looking beyond internal research to address gaps in oncology treatment. Since 2008, the company has supported early-stage researchers through the RSP, including Maria and Dr. Katherine Chiappinelli, an assistant professor at George Washington University. Katherine’s work focuses on ovarian cancer, and through the RSP, she is advancing research into epigenetic therapies aimed at stimulating the immune system to combat the disease.
Another RSP recipient, Dr. Neil Vasan—a physician-scientist at Columbia University Irving Medical Center—is exploring the role of oncoproteins in cancer signaling. His research zeroes in on rare PIK3CA mutations, and he is building a detailed “PIK3CA mutation playbook” to help inform breast cancer treatment decisions.
“Funding matters for several reasons,” Neil says. “It validates that your research is promising and could lead to meaningful change.”
Currently, Gilead’s oncology portfolio includes around 30 clinical-stage programs and over 20 potential therapies, covering a wide range of cancer types, particularly those with significant unmet needs.
Watch the video above to discover more about how Gilead continues to foster innovation in cancer research.
Companies